Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sun’s Ranbaxy Buy Out Could Have Implications For Nexium Generics

This article was originally published in PharmAsia News

Executive Summary

Ranbaxy’s ability to launch generic versions of AstraZeneca’s blockbuster Nexium in the U.S. on May 27 was uncertain already. Sun’s proposed $4 billion acquisition of Ranbaxy could further distract the troubled Indian generics firm from achieving that goal.

You may also be interested in...

Pfizer Expects OTC Nexium Will Launch With Market Exclusivity

Marketing exclusivity would be a key advantage as Nexium 24HR enters a crowded market of branded and private label OTC competitors. The NDA for Nexium 24HR included clinical data, Pfizer says, but whether FDA allowed Hatch-Waxman Act exclusivity for the product is not yet determined.

Nexium Direct: AstraZeneca’s Ambitious Test Of Direct-To-Consumer Sales

Nexium will ship directly to patients as the drug is about to become victim to generic competition, signaling AstraZeneca’s satisfaction with its Arimidex program.

AstraZeneca’s Promise To Investors: 10 New Drugs By 2020

CEO Pascal Soriot said the big pharma is on track to return to growth faster than anticipated, with 2017 revenues expected to be in line with 2013. A key driver of growth will be new drugs, many of which have been gained through deal-making and acquisitions.


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts